Summary
The effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the bladder (T1/G3 and >=T2) and the upper urinary tract were evaluated. Among a group of 136 patients (male 107, female 29) with such tumors, complete tumor resection was possible in 108, in whom durationof survival and disease-free interval with or without chemotherapy were compared. The combination of antineoplastic agents used was changed from 5-fluorouracil (5-FU)+vincristine (VCR)+bleomycin (BLM) or pepolomycin (PEP)+mitomycin C (MMC) or 5-FU+VCR+PEP+cyclophosphamide (CPM)+adriamycin (ADM) to CPM+ADM+cis-platinum (DDP) or methotrexate (MTX)+vinblastine (VBL)+ADM+DDP. Of the 59 patients in the chemotherapy group, 23 (39%) had side effects due to the treatment; however, fever and gastrointestinal symptoms were the chief adverse effects and were well tolerated. The 5-year survival rate and mean disease-free interval in the chemotherapy group were 76.3% and 24.6+ months, respectively, in bladder cancer patients, and 78.2% and 25.8+ months in those with upper urinary tract tumors. However, in the nonchemotherapy group (n=49) the corresponding values were 62.7% and 21.1+ months in patients with bladder cancer and 67.3% and 42.0+ months in those with upper urinary tract tumor. There was a statistically significant difference (P<0.05) in the disease-free intervals of the two treatment groups for bladder cancer patients. Recurrence, regardless of time, was observed in 25% of chemotherapy cases and in 65% of non-chemotherapy cases, and this difference was also statistically significant (P<0.001). These results suggest that adjuvant chemotherapy for uroepithelial transitional cell carcinoma may be effective in extending survival and significant by protracting the disease-free period, especially in cases of advanced bladder cancer.
Similar content being viewed by others
References
Akaza H, Koseki K, Kishi H, Umeda T, Isurugi K, Niijima T (1986) Muitidisciplinary treatment of invasive bladder cancer. Jpn J Urol 77: 716
Fujihiro S, Takeuchi T, Fujimoto Y, Okano M, Horie M, Kanematsu M, Kuriyama M, Ban Y, Nishiura T (1984) Chemotherapy of uroepithelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432. Jpn J Cancer Chemother 11: 427
Maatman TJ, Montie JE, Bukowski RM, Risius B, Geisinger M (1986) Intraarterial chemotherapy as an adjuvant to surgery in transitional cell carcinoma of the bladder. J Urol 135: 256
Montie JE, Straffon RA, Stewart BH (1984) Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol 131: 477
Obata K, Yamazaki Y, Murase T, Ueda K, Kuriyama M, Suzuki K, Yoshida K, Oshina S, Fujita T, Asano H, Suzuki S, Saito K, Isogai K, Naruse K (1986) Study of primary tumors of the bladder in the Tokai Urological Tumor Registry for 4 years. Jpn J Urol 77: 988
Obata K, Yamazaki Y, Murase T, Ueda K, Kuriyama M, Suzuki K, Yoshida K, Oshima S, Fujita T, Asano H, Suzuki S, Saito K, Isogai K, Naruse K (1986) Study of primary tumors of the renal pelvis and ureter in the Tokai Urological Tumor Registry for 4 years. Jpn J Urol 77: 995
Okada K, Yoshida T, Hirano D, Asaoka H, Kitamura K, Saito D, Kiyataki S, Sato Y, Kumagai S, Kitajima K, Kishimoto T (1985) Clinical study for the prognosis of the bladder tumor. Jpn J Urol 76: 1889
Pearson BS, Raghavan D (1985) First-line intravenous cisplatin for deeply invasive bladder cancer: Update on 70 cases. Br J Urol 57: 690
Skinner DG (1980) Current perspectives in the management of high grade invasive bladder cancer. Cancer 45: 1866
Soloway MS (1985) Overview of treatment of superficial bladder cancer. Urology 16 [Suppl]: 18
Whitmore WF Jr (1985) Chemotherapy for bladder cancer. J Urol 134: 1181
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuriyama, M., Takeuchi, T., Fujihiro, S. et al. Adjuvant chemotherapy for uroepithelial transitional cell carcinoma. Cancer Chemother. Pharmacol. 20 (Suppl 1), S29–S33 (1987). https://doi.org/10.1007/BF00262481
Issue Date:
DOI: https://doi.org/10.1007/BF00262481